Biotech & Life Sciences Marketing India ~ BioTech KPO

Biotech & Life Sciences Marketing India ~ BioTech KPO

Marketing to Life Scientists—Exploring India is designed to give suppliers a better understanding of the marketing media preferences in the emerging Biotechnology/ life science markets of India. It provides insights into how Indian scientists learn about new products and services and prefer to receive marketing communications.

Given the size of its English-speaking and scientifically skilled workforce in India, an increasingly favorable intellectual property environment, an extensive institutional network, and cost effective manufacturing, India has fast become a biotech and pharmaceutical industry leader in the Asia Pacific region.

Marketing Channels in India

Biotech KPO will provide essential insights into how scientists in India respond to various marketing media, enabling a smarter allocation of your company’s resources. For instance, Research& Markets found that Indian scientists typically spend about 2.5 hours per week visiting vendor Web sites. However, when they read a piece of direct mail and seek more information, these scientists are most likely to call their sales representative instead of visiting their website.

BioTech KPO will help you

Determine the most effective sales channel for India along with Recommendation of entering in market through Distributors or Direct.

Direct your advertising strategy for publications serving these markets
Tailor your eCommerce strategies for highest return
Maximize your conference exhibitors’ reach in the target markets.

About BioTech KPO

BioTech KPO is a Biotech Support services provider from India. Biotech KPO specializes in support services on very reasonable price. The company helps the Biotechnology and Pharmaceutical companies in their every type of activity.

Biotech KPO, team of Biotechnology Professional, providing these services from our state-of-art facility in New Delhi-India. For more information mail us info@biotechkpo.com or browse www.biotechkpo.com

Biotech Outsourcing India ~ Life Sciences Outsourcing~ Biotechnology Outsourcing India

Biotech Outsourcing India ~ Life Sciences Outsourcing~ Biotechnology Outsourcing India In India, the trend of business process outsourcing services started off only a decade ago. However, it is India, which is currently considered to be the best place to meet up with the outsourcing service requirements and to attain the best service globally. Today, the BPO/KPO outsourcing industry in India has been ranked as one of the most profitable industrial sectors in the nation. The industry stands responsible for accounting more than one third of the total productivity that has led the country to experience an increased rate of growth every year. Last but not least some India has its own advantages such as advanced infrastructure, low wages, and Massive youth power etc.etc. Biotech KPO provides following services at low cost from New Delhi India Life Sciences Strategic Partners · Potential R&D Partner for New/Existing Product Development · Potential OEM Partner · Potential Distributors Corporate Communication · Research Citation Tracking and updating · Media Tracking Research & Development · Potential R&D Partner for New/Existing Product Development · Commercial Prospects for New Products · Literature Review: What is hot in your area of Research and increasing your team’s · Competitor’s analysis · Sales and Marketing · Email Marketing & Lead Generation. · Technical Support through Emails/Phone to your clients. · Creating a Database of your potential clients. · Trade Show Identification · Market Size and Market Share · Google Adwords and Yahoo SEM Marketing. · Newsletter/Product Description Brochures / Announcements /Sales Letters. Data Sheets/MSDS · Products Literature collections Human Resource · Recruitment a highly Dedicated Lab Tech and Scientist team. Biotechnology/ Life Sciences Consultancy BioTech KPO 702, Somdatt Chambers–II 9, Bhikaiji Cama Place, New Delhi – 110066 Email: info@biotechkpo.com Web: www.biotechkpo.com

Biotech Outsourcing India ~ Life Sciences Outsourcing~ Biotechnology Outsourcing India

Life Sciences ~ Biotechnology Consultants India ~ Why to Choose India for Biotechnology Consultants?

Life Sciences ~ Biotechnology Consultants India ~ Why to Choose India for Biotechnology Consultants?

In the last couple of years, business process outsourcing has emerged to be one of the gifted sectors in the Indian market. In harmony with the latest surveys, the BPO/KPO services have progressively taken the Indian economy on a new height while another statistics depicting that by the year 2020, more than 80% of the world of business process outsourcing services will be served by the Indian companies.

In India, the trend of business process outsourcing services started off only a decade ago. However, it is India, which is currently considered to be the best place to meet up with the outsourcing service requirements and to attain the best service globally.

Today, the BPO/KPO outsourcing industry in India has been ranked as one of the most profitable industrial sectors in the nation. The industry stands responsible for accounting more than one third of the total productivity that has led the country to experience an increased rate of growth every year.

There are several factors that have contributed to the success of the BPO/KPO services in India. Some of these factors are given in the following lines:

Advanced infrastructure:

India is considered to be one of the fastest growing nations in the world. All the four metropolitan cities- Delhi, Chennai, Kolkata and Mumbai have turned out to be the major hub for almost each MNC from all over the world. These companies not only outsource the service requirements to different local companies but they also hire employees in order to handle its business operations residing in any other nations and also helping the partners as well. This is another reason behind the growth of the BPO/KPO services in India.

Lower wage:

India being one developing nation includes abundance of well-educated and well-trained people who can be easily employed for a relatively lower wage. As the labor cost is considered to be high in the developed nations, most companies belonging to the developed countries are found to be widely outsourcing their needs to the Indian BPO/KPO companies. Moreover, most BPO/KPO/call center firms are found to include youths, making them the primary workforce to reap the maximum benefits.

Adaptability to attain working style and foreign culture:

The Indian people are found to be pretty self-effacing when it is about getting adapted to the working style and foreign culture. Therefore, the foreign consumers usually find familiarity in India that makes them comfortable to carry out their outsourcing needs at ease. This serves to be an important reason that has made the BPO/KPO services in India a great pleasure for the service seekers from all over the world.

Massive youth power:

It may be surprising but true that almost 50 percent of the Indian population is young and almost all of them are educated individuals. As almost all of them are found to be professional graduates holding quality English speaking ability, they are mostly employed by the multinational companies and the other business outsourcing vendors situated in India. This proves to be the reason, which is offering an exceptional hike to the BPO/KPO services.

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Life Sciences  Biotechnology Consultants India

Biotech Product Development: Biotechnology & Life Sciences Products Developments

Biotech Product Development

The growth of a Biotechnology or Pharmaceutical company is no longer based upon his own laboratory. Less resources bounds a small Biotech startup to stay producing the products which they are selling already, but on the other hand new advance research motivate them to stay in market and keep adding new product in their portfolio. In my Past several years of experience I found that the small start ups have already a list of potential products which they want to add in their catalog but somehow due to lack of resources, they can not do the. If they do with the limited recourses then the quality of their existing, high selling products start decreasing.

Then a great question arises what a small startup with a less recourse do, to add the New Product in their portfolio????

This is where a startup needs a partnering company to help them to achieve these goals of adding New Products and staying in market with quality of existing products.

Biotech companies can explore the three different options for Biotech Product Development.

Biotech Product Development: Option I Start Producing in house with the help of other partner company (How to Choose a Biotech Support Partner)

Biotech Product Development: Option II Sub contracting he manufacturing of the Biotech Products/ R&D of Products to other partner companies? (How to Choose a Biotech Support Partner)

Biotech Product Development: Option III The third becomes the simple and of course the easy way of adding Products in the portfolio. That is do OEM for same products from other company. This is easy route but simultaneously less profitable. Even it is has lot of drawback in future if the product turns to be hot selling.

Biotech Support companies such as Biotech KPO (www.BioTechKPO.com ) will help you in Biotech Products Development, either you want in-house production or you want to subcontract your manufacturing or even you want to do OEM the products.

Click here for more information: www.biotechkpo.com/BIOTECHNOLOGY_STRATEGIC_PARTNERS.html

About BioTech KPO

BioTech KPO is a Biotech Support services provider from India. Biotech KPO specializes in support services on very reasonable price. The company helps the Biotechnology and Pharmaceutical companies in their every type of activity.
Biotech KPO, team of Biotechnology Professional, providing these services from our state-of-art facility in New Delhi-India. For more information mail us info@biotechkpo.com or browse www.biotechkpo.com

Biotech Support Services India

Biotech Support Services India~ Biotech KPO (www.biotechkpo.com) Call 91-11-41057783
Email: info@biotechkpo.com

A leading Life Sciences focused KPO on helping successful bioentrepreneur eliminating their
operating cost upto 45% through biotechnology
Consultancy outsourced to India which starts from $10 Per Hour:

Biotech/ Life Sciences Strategic Partners

* Potential R&D Partner for New/Existing Product Development
* Potential OEM Partner
* Potential Distributors

Corporate Communication

* Research Citation Tracking and updating
* Media Tracking

Research & Development

* Potential R&D Partner for New/Existing Product Development
* Commercial Prospects for New Products
* Literature Review: What is hot in your area of Research and increasing your team’s
* Competitor’s analysis
*

Sales and Marketing

* Email Marketing & Lead Generation.
* Technical Support through Emails/Phone to your clients.
* Creating a Database of your potential clients.
* Trade Show Identification
* Market Size and Market Share
* Google Adwords and Yahoo SEM Marketing.
* Newsletter/Product Description Brochures / Announcements /Sales Letters. Data Sheets/MSDS
* Products Literature collections

Human Resource

* Recruitment a highly Dedicated Lab Tech and Scientist team.

Biotechnology/ Life Sciences Consultancy

BioTech KPO

702, Somdatt Chambers–II
9, Bhikaiji Cama Place,
New Delhi – 110066

Tel: 91-11-41057783

Fax: +91 -11-6176067

Email: info@biotechkpo.com

Web: www.biotechkpo.com

Industry Watch??????????

Title:	Industry Watch
Abstract:	“Off-The-Shelf” Stem Cell Treatment for Heart Failure.Cytopia Cancer Program Reaches Important Milestone at Cancer Therapeutics CRC.Starpharma and Elanco Agree to Develop New Products.China Sky One Medical, Inc. Achieves Significant Breakthrough In Sudden Cardiac Death (SCD) Early Examination Kit.Roche Applied Science Opens Application Support Center in Shanghai.Luminex Expands Globally and Opens Facility in People’s Republic of China.Genesis Pharmaceuticals Launches Three New TCM Products.China Sky One Medical, Inc. to Develop New Anti-Cancer Drug with Taiwan Golden Biotechnology Corp.Solvay Pharmaceuticals Announces Strategic Partnership with HUYA to Access New Drug Candidates From China.Sinovac Receives $US12.9 mn Purchase Order for Healive® from China’s Ministry of Public Health.GE Launches Lullaby Warmer for Newborn in India.SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore.Aperio Expands Global Digital Pathology Presence with New Subsidiary in Asia.Valeant Pharmaceuticals Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange.Genome Institute of Singapore and Roche NimbleGen Develop Rapid Approach to Identify H1N1 Virus Mutations and Resistance to Drugs.
Keywords:	Patients; Product; Research; Cancer; Molecules; Vaccines; New born; Virus

An Investigation of OFDI Strategies in China’s Private Businesses: ‘Round- Tripping’ or ‘Onward-Journeyin

An Investigation of OFDI Strategies in China’s Private Businesses: ‘Round- Tripping’ or ‘Onward-Journeying’? Dr. Dylan Sutherland School of Contemporary Chinese Studies University of Nottingham Tel: 07762 350 433 (Dylan.sutherland@nottingham.ac.uk) FOR CONSIDERATION FOR JCEBS or ODS Abstract: Are the internationalization strategies of China’s financially constrained private businesses different from those of state-owned businesses? If so, how are they different? To date little systematic empirical research addresses these questions, despite the now well established arguments that market and institutional imperfections play an important role in the outward foreign direct investment (ODI) of large state business groups. Why is so little known about private sector ODI? One important reason is that private companies have gone to considerable lengths to conceal their ODI by using offshore holding companies, typically in tax havens and offshore financial centres. This paper, using a sample of publicly listed privately controlled companies, shows how the havens have been used and how private sector ‘onward-journey’ ODI (via tax havens) differs to that commonly ascribed to the state sector.

BIOTECHNOLOGICAL INNOVATIONS PATENT: A REVIEW

BIOTECHNOLOGICAL INNOVATIONS PATENT: A REVIEW

Rishabha Malviya*
, Vineet Bhardwaj, Pranati Srivastava, Mayank Bansal, Pramod Kumar Sharma
Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Baghpat By-Pass, Delhi -
Roorki Highway, Meerut-250005, U.P., India.
*Email: rishabhamalviya19@gmail.com

ABSTRACT
This  article  evaluates patent  protection  as  an  incentive mechanism  for  biotechnology      innovation  in  India, Recent  enhancements  to
India’s patent laws, a new acceptance of biotechnology patents. It analyses the international patenting trends, patents that have significant
impact and countries active in patenting. It also examines Indian patenting activity and its comparison with international trends to assess
the  Indian  efforts.  The  patentability  of  products  is  essential  in  the  biotechnology  field,  for  limited market  exclusivity  compensates
biotech companies’ investments in research and development. The biotechnology field also uniquely faces Federal Drug Administration
(FDA) approval, which includes considerable additional expense and time issues a biotech company must address.
Keywords: Biotechnology, patents, proprietary right, patenting trends.

Biotech Services India~ Biotech KPO (www.biotechkpo.com) Call 91-11-41057783 Just Shoot an Email: info@biotechkpo.com

Biotech Services India~ Biotech KPO (www.biotechkpo.com) 
Call 91-11-41057783 Just Shoot an Email: info@biotechkpo.com

A leading Life Sciences focused KPO on helping successful 
bioentrepreneur eliminating their operating cost upto 45% 
through biotechnology Consultancy outsourced to India which
 starts from $10 Per Hour:

Biotech/ Life Sciences Strategic Partners

• Potential R&D Partner for New/Existing Product Development
• Potential OEM Partner
• Potential Distributors

Corporate Communication

• Research Citation Tracking and updating
• Media Tracking

Research & Development

• Potential R&D Partner for New/Existing Product Development
• Commercial Prospects for New Products
• Literature Review:  What is hot in your area of Research and increasing your team’s
• Competitor’s analysis

Sales and Marketing

• Email Marketing & Lead Generation.
• Technical Support through Emails/Phone to your clients.
• Creating a Database of your potential clients.
• Trade Show Identification
• Market Size and Market Share
• Google Adwords and Yahoo SEM Marketing.
• Newsletter/Product Description Brochures / Announcements /Sales Letters. Data Sheets/MSDS
• Products Literature collections

Human Resource

• Recruitment a highly Dedicated Lab Tech and Scientist team.

Biotechnology/ Life Sciences Consultancy

BioTech KPO

702, Somdatt Chambers–II
9, Bhikaiji Cama Place,
New Delhi – 110066

Tel: 91-11-41057783

Fax: +91 -11-6176067

Email: info@biotechkpo.com

Web: www.biotechkpo.com

BioPharma to grow over 10% for next 5 years

BioPharma to grow over 10% for next 5 years

Monday, June 14, 2010

BioPharma to grow over 10% for next 5 years •  BioPharma clocks Rs 8,829 crore in revenues •  It accounted for 62% of the total revenue and grew by 12% over FY 2008-09 •  The Top 20 BioPharma companies contributed close to Rs 6000 crore The Indian BioPharma market comprising primarily of vaccines, therapeutic drugs, insulin, animal biologicals, statins and diagnostics in 2009-2010, continued to grab the largest share of the total biotech industry revenues of over Rs 14,199 crore. It contributed Rs 8,829 crore, accounting for 62 percent market share. Vaccines had the largest pie with an estimated sales of Rs 2,180 crore over last year’s figure of Rs 2,000 crore. The vaccine segment-human as well as animal vaccines-accounted for 50-60 percent of the total BioPharma market. Total estimated sales from the human vaccine business stood at Rs 1,750 crore over the 2008-2009 figure of Rs 1,550 crore. Domestic sales of human vaccines just about crossed Rs 1,000 crore. In FY 2008-09 this figure stood at Rs 900 crore. Export sales is estimated to have generated Rs 750 crore, as compared to Rs 650 crore in FY 2008-09. Animal Vaccines registered a marginal decline with sales of Rs 430 crore over last year’s figure of Rs 450 crore. In animal vaccines, poultry vaccines clocked Rs 220 crore, cattle and sheep vaccines registered Rs 210 crore. The vaccine market will continue to drive the growth of the biopharma segment growing in the range of 10-13 percent in the next 5 years. The factors that will drive this include education and awareness about disease prevention, increase in disposable income and participation by government. The market will clearly shift to combination vaccines such as Pentavalent vaccines. Domestic players such as Bharat Biotech and Shantha Biotech have already received massive orders from the Government of India for immunization programmes in Himachal Pradesh, Kerala, Tamil Nadu, Jammu and Kashmir and Karnataka. There is going to be a change from largely whole-cell pertusis -based combos to acellular-based combos in the coming years. Newer vaccines like Pneumo conj, Meninge Conj and HPV would drive the market growth in paediatric and adolescent segment, while Flu will continue to be a big driver in the adult market segment. A noteworthy product launched during 2009-2010 was Shantha’s Shanchol-India’s first oral vaccine to protect against cholera. Shanchol is a bivalent inactivated-whole-cell oral cholera vaccine developed by Shantha in collaboration with the International Vaccine Institute (IVI), Seoul, Korea. Driven by a rise in chronic diseases and investments in the healthcare infrastructure, diagnostics and therapeutics business also had a positive impact on the industry. The diagnostic market is estimated to be at Rs 2,000 crore with molecular diagnostic market share at $300 million in FY 2009-2010. This accounts for 20-22 percent share of the total BioPharma market. A highly competitive segment, the market currently is growing at 15-20 percent with a 50:50 revenue share split between MNCs and homegrown companies. Major MNC companies in the diagnostic market include Roche, Siemens (which has acquired Bayer Diagnostics) and Abbott while homegrown names in the top league include Tulip Group, Transasia Biomedicals, RFCL (Diagnova), Span Diagnostics and Trivitron. This growth is driven from the gradual acceptance of the concept of preventive and personalized medicine. The therapeutics market claimed 15 percent of market share in FY 2009-2010 with the cancer therapeutics sales clocking Rs 311 crore. Companies in the segment are now moving towards novel targeted therapies and supportive care products. Cancer therapeutics is a lucrative business for many Indian companies because of high unmet needs, high prices of innovator drugs, increase of awareness and affordability. These homegrown players will play a pivotal role in reducing the price points of important cancer drugs. The market size of Oral Diabetes Drugs is estimated to be Rs 1,550 crore and market size of Insulin (including analogs) is approximately Rs 612 crore. The large market size is reflective of India  emerging as the diabetes capital of the world. Between 1995 and 2005 the number of diabetic patients doubled from 20 million to 40 million and this is projected to grow to 70 million patients by 2025. In Insulin (including Analog) segment, Novo Nordisk is the market leader with over 50 percent market share while Eli Lilly has 22 percent market share. Analogs which currently contribute 27 percent in value (8 percent in volume) are the fastest growing segment (with 2007-09 CAGR of 32 percent) in value. Within insulin market, novel delivery devices would be the growth drivers in the coming years. Biogenerics segment in the near term will be a key growth driver for Indian players especially with the US set to establish a biogenerics (biosimilars) pathway by 2013. In India, Erythropoietin (EPO)  clocked a sales of Rs 10 lakh ($22,000), c-GSF-Rs 5 lakh ($11000), interferon–Rs 10 lakh $22000 and streptokinase Rs 7 lakh ($16000). These products are been sold at price discounts of upto almost  85 percent of its innovator drug thus making them affordable to the masses. Currently, Dr Reddy’s Labs, Ranbaxy, Biocon, Shantha Biotechnics and Intas Biopharmaceuticals are actively involved in the space. There are around 25 Indian players with over 50 products already being sold in the Indian market and some being sold in the unregulated markets as well. Other prominent companies that have started initiatives in the field include Glenmark, Cipla and Lupin Pharma. Last year, Cipla entered into a 50:50 joint venture (JV) with a Chinese company for biosimilars. The JV would be called Biomab and Cipla is likely to bring out Biomab’s first product later this year. Top 20 BioPharma Companies by Revenue (2009-10) Revenue Rank 2010 Company 2009-10 (Revenue in  Rs Cr) 2008-09 (Revenue in Rs Cr) % Change Over 2008-09 1 Biocon 1180 912.34 29.34 2 Serum Institute of India* 850 1114.00 -23.7 3 Panacea Biotec 703.19 597.14 17.76 4 Reliance Life Sciences* 450 - - 5 NovoNordisk* 342 330.00 3.64 6 Shantha Biotech 334.23 247.00 35.32 7 Indian Immunologicals 272.87 231.46 17.89 8 Bharat Biotech 271.66 241.05 12.7 9 Eli Lilly 187 164.00 13.85 10 Bharat Serums 175 140.00 25 11 Haffkine Biopharma 168.98 - - 12 Cadila Healthcare 147.48 93.70 57.4 13 GlaxoSmithKline 123.34 83.48 47.75 14 Intervet India 121.6 - - 15 Intas Biopharma 115 89.27 28.82 16 Themis Medicare 112.12 97.50 14.99 17 Concord Biotech 111.7 52.13 114.27 18 Venkateshwara Hatcheries* 90 - - 19 Aventis Pharma 68.34 36.00 89.83 20 Dr Reddy’s Laboratories 62.5 40.00 56.25 * BioSpectrum estimates All figures in Rs. Crore unless indicated otherwise

Source: BioSpectrum